Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib +/- Bevacizumab in mCRC (LYNK-003)
NCT04456699Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of olaparib in metastatic colorectal cancer (mCRC), sponsored by Merck & Co.. Started Aug 2020; status: completed.
02
Drugs
olaparib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04456699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04456699.